What is missing There is no published human pharmacokinetic study of subcutaneous AOD-9604, no published human topical or intranasal exposure data, no Phase 3 efficacy trial, no long-term safety data beyond 24 weeks, and no published human cartilage or joint outcome data
The free FormBlends consultation covers your specific concerns, including how aod-9604 for gut health has been handled for patients in similar situations
Your provider at Renew Wellness & Aesthetics personalizes a schedule based on your blood work, energy needs, and metabolic support, ensuring you receive maximum absorption and long-lasting benefits without overloading your system
Neither route is proven better in people
The Month 2 dose increase is data-driven, not arbitrary